Bluejay Therapeutics is focused on developing innovative cures for infectious diseases with the first target indication of chronic HBV infection.
Total raised: $182M
Investors 2
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
| 05.09.2022 | Arkin Hold... | arkinholdi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.05.2024 | Series C | $182M | - |
Mentions in press and media 4
| Date | Title | Description |
| 09.05.2024 | Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline | - |
| 09.05.2024 | Bluejay Therapeutics Raises $182M in Series C Financing | Bluejay Therapeutics, a San Mateo, CA-based company which specializes in the development of novel therapeutics, raised $182M in Series C funding. The round was co-led by Frazier Life Sciences with participation from both new and existing in... |
| - | Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline | Bluejay Therapeutics, a leader in developing novel therapeutics, today announced the successful closure of a $182 million Series C financing round. This capital infusion will accelerate the clinical development of BJT-778, as the treatment ... |
| - | Bluejay Therapeutics | “Bluejay Therapeutics, Inc. is a private biopharmaceutical company illuminating a path toward curative treatments for viral infections and liver diseases, including for CHB and CHD.” |